Department of Veterinary Diagnostic and Production Animal Medicine, Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University, 1850 Christensen Drive, Ames, IA 50011, USA.
Department of Biological Sciences, Northern Illinois University, DeKalb, IL 60115, USA.
Virus Res. 2023 Apr 2;327:199078. doi: 10.1016/j.virusres.2023.199078. Epub 2023 Feb 22.
Human coronavirus NL63 (HCoV-NL63) is spread globally, causing upper and lower respiratory tract infections mainly in young children. HCoV-NL63 shares a host receptor (ACE2) with severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 but, unlike them, HCoV-NL63 primarily develops into self-limiting mild to moderate respiratory disease. Although with different efficiency, both HCoV-NL63 and SARS-like CoVs infect ciliated respiratory cells using ACE2 as receptor for binding and cell entry. Working with SARS-like CoVs require access to BSL-3 facilities, while HCoV-NL63 research can be performed at BSL-2 laboratories. Thus, HCoV-NL63 could be used as a safer surrogate for comparative studies on receptor dynamics, infectivity and virus replication, disease mechanism, and potential therapeutic interventions against SARS-like CoVs. This prompted us to review the current knowledge on the infection mechanism and replication of HCoV-NL63. Specifically, after a brief overview on the taxonomy, genomic organization and virus structure, this review compiles the current HCoV-NL63-related research in virus entry and replication mechanism, including virus attachment, endocytosis, genome translation, and replication and transcription. Furthermore, we reviewed cumulative knowledge on the susceptibility of different cells to HCoV-NL63 infection in vitro, which is essential for successful virus isolation and propagation, and contribute to address different scientific questions from basic science to the development and assessment of diagnostic tools, and antiviral therapies. Finally, we discussed different antiviral strategies that have been explored to suppress replication of HCoV-NL63, and other related human coronaviruses, by either targeting the virus or enhancing host antiviral mechanisms.
人冠状病毒 NL63(HCoV-NL63)在全球范围内传播,主要导致婴幼儿上呼吸道和下呼吸道感染。HCoV-NL63 与人严重急性呼吸综合征冠状病毒(SARS-CoV)和 SARS-CoV-2 共享宿主受体(ACE2),但与它们不同的是,HCoV-NL63 主要发展为自限性的轻度至中度呼吸道疾病。尽管效率不同,但 HCoV-NL63 和 SARS 样冠状病毒均使用 ACE2 作为受体结合和进入细胞,感染纤毛状呼吸道细胞。与 SARS 样冠状病毒合作需要进入 BSL-3 设施,而 HCoV-NL63 研究可以在 BSL-2 实验室进行。因此,HCoV-NL63 可作为一种更安全的替代品,用于比较 SARS 样冠状病毒受体动力学、感染性和病毒复制、疾病机制以及潜在治疗干预措施的研究。这促使我们回顾了 HCoV-NL63 的感染机制和复制的现有知识。具体而言,在简要概述分类、基因组组织和病毒结构之后,本综述汇编了当前关于 HCoV-NL63 病毒进入和复制机制的相关研究,包括病毒附着、内吞作用、基因组翻译以及复制和转录。此外,我们还回顾了不同细胞对 HCoV-NL63 体外感染易感性的累积知识,这对于成功进行病毒分离和繁殖至关重要,并有助于解决从基础科学到诊断工具的开发和评估以及抗病毒疗法的不同科学问题。最后,我们讨论了不同的抗病毒策略,这些策略旨在通过靶向病毒或增强宿主抗病毒机制来抑制 HCoV-NL63 和其他相关人类冠状病毒的复制。